SRSD107
Phase 2Small molecule
SRSD107 is one of 77 small molecule programs targeting Efficacy and Safety. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
242 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Savaysa
Daiichi SankyoPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Rilutek
AAzurity Pharmaceuticals
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
Glypressin
MMallinckrodt
Phase 3
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 3
Becotatug Vedotin
FFudan University
Phase 3
Apatinib Mesylate
BBukwang Pharmaceutical
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Peripheral Arterial Disease1 trial
Phase 11 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SRSD107. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSirius Therapeutics Co., Ltd.